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Background: We present a case series of a palliative radiofrequency ablation (RFA) for the tumors that lead to the
resolution of pain and motor function disorders. RFA is widely used on tumors in various organs and often reported
in good outcome. There are some reports that RFA was performed as a palliative treatment but a few reports of
RFA that performed for lung tumor as a palliative treatment. This case series includes two cases, palliative RFA for a
sacrum and a lung tumor. The results of this case series presented that a palliative RFA is effective in improving the
symptoms of patients.
Case presentation: Case 1. A 64-year-old Japanese woman with a chordoma at her sacrum presented with pain in her
left leg and claudication. Though operations, radiation therapy and GS-TAE (gelatin sponge–transarterial embolization, via
the L5 lumbar artery) were performed, the size of the tumor leading pain and claudication increased. RFA was performed
for the sacral tumor, and these symptoms resolved one year after the procedure.
Case 2. A 68-year-old Japanese man with a leiomyosarcoma at the apex of left lung presented with pain and
motor function disorders of the left upper limb. Dissemination in the pleura was appeared after the operation for
a leiomyosarcoma at the mediastinum. Though radiation therapy and a second operation were performed, the tumor
at the apex of the left lung increased and pain and numbness of the left upper limb were appeared after the second
operation. RFA was performed for the left lung tumor, and the symptoms resolved 3 months after RFA.
Conclusion: RFA is effective as a palliative treatment and has a potential to salvage the patients from the symptoms of
the tumors when conventional palliative treatments such as surgery, radiation therapy, and chemotherapy are difficult
or contraindicated.
Keywords: Radiofrequency ablation, Palliative treatment, Carcinomatous neuropathyBackground
Radiofrequency ablation (RFA) is the treatment to malig-
nant tumors by inserting an electrode into the tumor and
causing the thermocoagulation necrosis of the tumor [1].
RFA is a minimally invasive therapy and has a low risk
of major complications [2]. At present, RFA is widely
used on tumors in various organs and results in good
outcome [1,3]. It has been reported that RFA is also ef-
fective for the palliative treatment [4]. A palliative RFA
is performed when conventional palliative treatments
such as surgery, radiation therapy, and chemotherapy* Correspondence: hamashin_tigers1975@yahoo.co.jp
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article, unless otherwise stated.are difficult or contraindicated. It has not previously
been well established in the literature if a palliative RFA
for the pulmonary tumor is effective. These cases con-
sist of two patients, a sacrum tumor and pulmonary
tumor with pain and neuropathy that received palliative




A 64-year old Japanese woman underwent resection of a
sacral chordoma. Recurrence of tumor appeared 7 years
later, and thus reoperation was performed. Tumor recur-
rence was observed at 2 and again at 4 years after the reop-
eration. Therefore, radiation therapy (total dose: 51 Gy)tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Case 1: Non-contrast CT on the first session of tumor ablation. A LeVeen electrode is located in the center of the tumor
(arrowhead). This ablation was stopped before reaching “roll-off” because the patient complained of left leg pain and numbness.
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via the L5 lumbar artery) were performed. However, the
tumor increased in size and was accompanied by pain and
claudication. Before RFA, she had been unable to sit
due to complaints of pain and claudication in her left
leg. Non-contrast computed tomography (CT) showed
that the tumor was in the sacrum, and thus provided
evidence that the symptoms were due to compression
of the sciatic nerve.
After informed consent was obtained RFA was per-
formed. A 13-gauge needle was inserted in the cortex of
the sacrum with CT guidance under local anesthesia. AFigure 2 Case 1: Contrast-enhanced CT about 1 year after RFA. The sa
progressed dorsally to the lateral of sacrum (white thin arrow).LeVeen electrode was inserted coaxially in the tumor via a
13-gauge needle, and retractable hooks were opened
(Figure 1). Ablation was performed four times, shifting
the position of the electrode for every ablation. The
starting output was 10 W, which was increased 10 W
every 2 minutes. Ablation continued until the generator
automatically stopped upon reaching the maximum re-
sistance due to increased impedance (i.g. roll off ). Abla-
tion was started with the low output and if a sharp pain
of her legs appeared, ablation was stopped in order to
avoid the damage of nervous by heat. Total ablation
time was 29 minutes and 39 seconds, and maximumcral tumor did not increase (white arrow). However, the tumor
Figure 3 Case 2: Contrast-enhanced CT pre-RFA. A large tumor (over 10 cm in largest diameter) is observed in the apex of the left lung. This
tumor contains a low-density area considered to be necrosis and enhanced solid lesion (white arrow).
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cycles due to the pain in her left leg before “roll-off”.
The pain and numbness in her left lower leg resolved
immediately after the RFA procedure. The next day, the
claudication had disappeared and it became possible for
the patient to sit down. One year after RFA, the pain
had not recurred and no increase in tumor size was re-
vealed on CT (Figure 2).
Case 2
A 68-year-old Japanese man underwent resection of a
leiomyosarcoma at the mediastinum. Dissemination in the
pleura was observed, and thus radiation therapy (total
dose: 40 Gy) and a second operation were performed. PainFigure 4 Case 2: Non-contrast CT on the first ablation session. A LeVe
hooks are fully opened (arrowhead). In this session, “roll-off” was not obtainand numbness of the left upper limb developed 10 months
after the second operation and contrast enhanced CT scan
was performed. Contrast enhanced CT scan showed a
tumor at the apex of the left lung, accompanied by an en-
hanced solid lesion and a non-enhanced cystic lesion
(Figure 3). The development of pain and numbness was
observed at the lateral side of left antebrachium, digitus
medius and anularis. The patients had the motor function
disorder of left arm that he could not have or hold by left
arm. RFA was chosen because it was thought that radi-
ation and chemotherapy would not be effective and that
surgery has a high risk of bleeding.
RFA was performed with patient consent. A LeVeen
electrode was inserted in the tumor with CT guidanceen electrode is located near the center of the tumor, and retractable
ed even though ablation was continued for 20 minutes.
Figure 5 Case 2: Non-contrast CT (coronal reformatted image) after the first ablation session. The retractable hooks do not reach the
chest wall.
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electrode was mostly located in the center of the tumor
and it was confirmed that the electrode and plexus bra-
chialis were fully separated on CT in order to avoid the
damage of plexus brachialis by ablation. This procedure
was performed under local anesthesia to monitor the
appearance of sharp pain of left upper limb. The output
was started at 20 W, and then increased by 10 W every
2 minutes. In each session, ablation continued until “roll
off” and maximum ablation time was decided 20 minutes
when “roll off” was not obtained. Ablation was interruptedFigure 6 Case 2: Contrast-enhanced CT 2 days after RFA. Complication
intratumoral enhanced solid lesion is smaller compared to findings on pre-if a sharp pain of left upper limb appeared. Ablation was
performed three times. The output was started at 20 W,
and then increased by 10 W every 2 minutes. Total abla-
tion time was 57 minutes and 14 seconds, and maximum
output was 80 W. “Roll-off” was obtained only in the third
session of ablation.
Contrast enhanced CT performed 2 days after RFA
showed that the enhanced solid lesion in the tumor was
smaller in size compared to pre-RFA CT (Figure 6). A
pain had disappeared for about 3 months after RFA,
accompanied by an improvement in motor functions such as pneumothorax or hemorrhage are not observed. The
RFA CT (white arrow).
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ever, 3 months after RFA, the pain of the left upper
limb re-appeared due to growth of the tumor.
Conclusion
Palliative RFA was performed to relieve symptoms in-
duced by tumor in two cases, leading to the resolution
of pain and motor function disorders in both. Therefore,
RFA was found to be an effective palliative treatment.
At present, surgery for reduction of tumor volume, ra-
diation therapy and chemotherapy have been performed
as palliative treatments for relief of symptoms induced
by tumors that cannot be radically resected [4]. However,
these treatments have some limits. Surgical operation has
a risk of bleeding and technical difficulties due to the size
of tumors or adhesions. Radiation therapy is complicated
by dose limitations in relation to re-irradiation, and it
often takes several weeks before therapy is complete and
relief of accompanying symptoms is achieved. Further-
more, radiation therapy has the risk of complications such
as neuropathy and radiation pneumonitis [5].
Some reports have shown that ablation therapy is ef-
fective and safety palliative treatment for the relief of
symptoms induced by tumor [4,6]. Tumors can cause
symptoms such as pain or motor function disorders in
several ways. They can compress adjacent structures or
nerves, increase intratumoral or interstitial pressure, or
release cytotoxic substances [7]. RFA can provide pain
relief through thermal coagulation necrosis and reduc-
tion of tumor volume. These processes subsequently re-
duce tumor compression of surrounding internal organs
and nerves. Furthermore, coagulation necrosis leads to
decreased production of cytotoxic substances released
from the tumor [7].
Palliative RFA has some advantages compared to other
palliative treatments. First, RFA is completed in 1 day
and often provides rapid pain relief. Effects of RFA are
observed immediately after the procedure and may rap-
idly improve quality of life. Second, RFA is minimally in-
vasive and can be performed under local anesthesia. It
has also been reported to have a low risk of major com-
plications [2]. Furthermore, RFA can be performed re-
peatedly as long as the electrode puncturing procedure
is technically possible. Repeat RFA has an opportunity to
salvage tumors that progressed locally after the first RFA
[8]. RFA may promote neuropathy since the temperature
around the electrode rises and heat may spread in the
adjacent structures (such as nerves). Therefore, physi-
cians must monitor the ongoing possibility of neur-
opathy development during ablation. When neuropathy
does develop, ablation of a tumor has to be aborted. In the
cases of RFA tumor ablation presented in this report, the
relief of symptoms were obtained though incomplete
tumor ablation. Since palliative RFA is a medical treatmentaimed at symptom relief, careful attention must be paid to
the procedure.
Palliative RFA is an effective treatment for the relief of
pain or the improvement of motor function disorders.
Palliative RFA has a potential to salvage the patients
from the symptoms of the tumors when conventional
palliative treatments such as surgery, radiation therapy,
and chemotherapy are difficult or contraindicated.
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